SEP 15·SEC EDGARLow
Ball Robert Joseph sold $188K of SI
Ball Robert Joseph (CEO & Executive Chairman) sold 10,175 shares of SHOULDER INNOVATIONS, INC. (SI) at $18.45 ($0.19M total) on 2026-09-14.
StockNYSE · US · USDTechnology · GENERAL
$SI
SHOULDER INNOVATIONS, INC.
AlphAI earnings readsecond quarter 2026 · AUG 6Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year OutlookVerdict: solidRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $SIvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $SI in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $1.1M 7 txs
Gilde Healthcare Holding B.V.4× · $594K
10b5-1 share of filings29%
Top stories · $SIMore →
SEP 10·orthospinenews.com
22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News
Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant
SEP 9·prnewswire.com
Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures
Shoulder Innovations (NYSE: SI) and ALM Ortho partnered to develop personalized shoulder implants for complex cases. SI gains exclusive U.S. rights for upper extremity applications. The deal aims to address unmet needs and drive growth, though financial terms are confidential.
SI sentiment & insider activity
Recent SI coverage spans insider activity, financial news and earnings.
In the last 30 days, SI insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($1.1M). The most active reporter was Gilde Healthcare Holding B.V. with 4 filings. 29% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving SI
Insider sale may signal lack of confidence, but size is modest.
The clearance opens a new market segment for metal‑hypersensitive patients, potentially boosting sales and market share.
The collaboration could expand SI's product portfolio and drive incremental revenue.
The settlement removes legal uncertainty, potentially supporting the stock.
Gilde Healthcare Holding B.V. sold 25,097 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.61 ($22.60–$22.62, $0.57M total) across 3 trades over 2026-08-20 to 2026-08-24.
AlphAI scores every news story that mentions SI with an AI model for sentiment and relevance, and aggregates insider trades from SHOULDER INNOVATIONS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $SI
Score
Ball Robert Joseph sold $188K of SI
Ball Robert Joseph (CEO & Executive Chairman) sold 10,175 shares of SHOULDER INNOVATIONS, INC. (SI) at $18.45 ($0.19M total) on 2026-09-14.
1 min read
22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News
Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant
2 min read
Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures
Shoulder Innovations (NYSE: SI) and ALM Ortho partnered to develop personalized shoulder implants for complex cases. SI gains exclusive U.S. rights for upper extremity applications. The deal aims to address unmet needs and drive growth, though financial terms are confidential.
1 min read
Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience
Shoulder Innovations (NYSE: SI) settled patent litigation with Catalyst OrthoScience. Terms are confidential. The company focuses on shoulder surgical care and aims to advance arthroplasty. CEO Rob Ball emphasized protecting intellectual property to benefit stakeholders.
1 min readGilde Healthcare Holding B.V. sold $567K of SI (indirect holdings)
Gilde Healthcare Holding B.V. sold 25,097 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.61 ($22.60–$22.62, $0.57M total) across 3 trades over 2026-08-20 to 2026-08-24.
1 min readShoulder Innovations Q2 Earnings Call Highlights
Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.
6 min readShoulder Innovations (SI): Gilde Healthcare sells shares, holds 10.7% stake
According to a Form 10-K filed May 13, 2026, Gilde Healthcare and related Dutch entities hold 2,212,207 shares of Shoulder Innovations, Inc. common stock, or 10.7% based on 20,738,226 shares outstanding as of May 6, 2026. The filing also reports open-market sales in late July to early August 2026, including 99,812 shares sold Aug. 4 at a weighted average $22.77.
2 min readGilde Healthcare Holding B.V. sold $213K of SI (indirect holdings)
Gilde Healthcare Holding B.V. sold 9,433 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.63 ($22.60–$22.64, $0.21M total) across 2 trades over 2026-08-05 to 2026-08-06.
2 min read
Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook – Ortho Spine News
Shoulder Innovations (NYSE: SI) reported Q2 2026 net revenue of $17.2 million, up 56% year over year, with gross margin of 78.3%. Full-year 2026 net revenue guidance was raised to $67 million to $69 million. Cash and marketable securities totaled $99.0 million as of June 30, 2026.
4 min read
Siemens to acquire EDA software firm Precision Innovations
Siemens said it signed an agreement to acquire privately held US EDA software firm Precision Innovations. Siemens said the deal will add AI-powered chip planning and early design exploration using the OpenROAD framework to help semiconductor teams optimize power, performance and area, reduce iterations, and speed SoC feasibility analysis and time to market.
2 min read